Table 3.
Antihypertensive therapy use at baseline and Week 26
| Time point | Placebo | Ertugliflozin 5 mg | Ertugliflozin 15 mg |
|---|---|---|---|
| Patients with one or more antihypertensive therapies | |||
| Baselinea | 337 (65.4) | 353 (68.0) | 336 (65.9) |
| Week 26b | 316 (66.8) | 344 (69.5) | 318 (67.5) |
| RAAS blockers | |||
| Baselinea | 292 (56.7) | 306 (59.0) | 289 (56.7) |
| Week 26b | 278 (58.8) | 298 (60.2) | 271 (57.5) |
| β blockers | |||
| Baselinea | 120 (23.3) | 104 (20.0) | 98 (19.2) |
| Week 26b | 113 (23.9) | 101 (20.4) | 96 (20.4) |
| Calcium channel blockers | |||
| Baselinea | 94 (18.3) | 91 (17.5) | 116 (22.7) |
| Week 26b | 88 (18.6) | 93 (18.8) | 108 (22.9) |
| Diuretics | |||
| Baselinea | 106 (20.6) | 112 (21.6) | 104 (20.4) |
| Week 26b | 99 (20.9) | 106 (21.4) | 98 (20.8) |
| Other antihypertensive therapy | |||
| Baselinea | 22 (4.3) | 18 (3.5) | 18 (3.5) |
| Week 26b | 22 (4.7) | 18 (3.6) | 18 (3.8) |
Every patient is counted a single time for each applicable specific medication. A patient with multiple medications within a medication category is counted a single time for that category. Data presented as number of patients (%)
RAAS renin–angiotensin–aldosterone system
aNumber of patients with data: 515 (placebo), 519 (ertugliflozin 5 mg), and 510 (ertugliflozin 15 mg)
bNumber of patients with data: 473 (placebo), 495 (ertugliflozin 5 mg), and 471 (ertugliflozin 15 mg)